MoonLake Immunotherapeutics (MLTX) Competitors $55.89 +1.72 (+3.18%) Closing price 08/22/2025 04:00 PM EasternExtended Trading$54.75 -1.14 (-2.04%) As of 08/22/2025 06:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock MLTX vs. VTRS, ASND, RDY, QGEN, MRNA, BBIO, VRNA, ELAN, BPMC, and ROIVShould you be buying MoonLake Immunotherapeutics stock or one of its competitors? The main competitors of MoonLake Immunotherapeutics include Viatris (VTRS), Ascendis Pharma A/S (ASND), Dr. Reddy's Laboratories (RDY), Qiagen (QGEN), Moderna (MRNA), BridgeBio Pharma (BBIO), Verona Pharma PLC American Depositary Share (VRNA), Elanco Animal Health (ELAN), Blueprint Medicines (BPMC), and Roivant Sciences (ROIV). These companies are all part of the "pharmaceutical products" industry. MoonLake Immunotherapeutics vs. Its Competitors Viatris Ascendis Pharma A/S Dr. Reddy's Laboratories Qiagen Moderna BridgeBio Pharma Verona Pharma PLC American Depositary Share Elanco Animal Health Blueprint Medicines Roivant Sciences MoonLake Immunotherapeutics (NASDAQ:MLTX) and Viatris (NASDAQ:VTRS) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, dividends, risk, institutional ownership, earnings, media sentiment, analyst recommendations and profitability. Does the media favor MLTX or VTRS? In the previous week, MoonLake Immunotherapeutics had 2 more articles in the media than Viatris. MarketBeat recorded 6 mentions for MoonLake Immunotherapeutics and 4 mentions for Viatris. MoonLake Immunotherapeutics' average media sentiment score of 0.23 beat Viatris' score of 0.00 indicating that MoonLake Immunotherapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment MoonLake Immunotherapeutics 2 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Viatris 0 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Which has more volatility & risk, MLTX or VTRS? MoonLake Immunotherapeutics has a beta of 1.27, indicating that its share price is 27% more volatile than the S&P 500. Comparatively, Viatris has a beta of 0.9, indicating that its share price is 10% less volatile than the S&P 500. Which has stronger earnings and valuation, MLTX or VTRS? MoonLake Immunotherapeutics has higher earnings, but lower revenue than Viatris. MoonLake Immunotherapeutics is trading at a lower price-to-earnings ratio than Viatris, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMoonLake ImmunotherapeuticsN/AN/A-$118.94M-$2.78-20.10Viatris$14.12B0.88-$634.20M-$2.90-3.67 Do insiders and institutionals hold more shares of MLTX or VTRS? 93.9% of MoonLake Immunotherapeutics shares are held by institutional investors. Comparatively, 79.9% of Viatris shares are held by institutional investors. 12.0% of MoonLake Immunotherapeutics shares are held by insiders. Comparatively, 0.1% of Viatris shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. Do analysts recommend MLTX or VTRS? MoonLake Immunotherapeutics currently has a consensus price target of $74.43, suggesting a potential upside of 33.17%. Viatris has a consensus price target of $10.40, suggesting a potential downside of 2.35%. Given MoonLake Immunotherapeutics' stronger consensus rating and higher probable upside, equities research analysts plainly believe MoonLake Immunotherapeutics is more favorable than Viatris.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score MoonLake Immunotherapeutics 0 Sell rating(s) 2 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 2.78Viatris 2 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 1.80 Is MLTX or VTRS more profitable? MoonLake Immunotherapeutics has a net margin of 0.00% compared to Viatris' net margin of -24.57%. Viatris' return on equity of 16.54% beat MoonLake Immunotherapeutics' return on equity.Company Net Margins Return on Equity Return on Assets MoonLake ImmunotherapeuticsN/A -40.98% -35.81% Viatris -24.57%16.54%7.06% SummaryMoonLake Immunotherapeutics beats Viatris on 11 of the 15 factors compared between the two stocks. Get MoonLake Immunotherapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for MLTX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding MLTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MLTX vs. The Competition Export to ExcelMetricMoonLake ImmunotherapeuticsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$3.48B$3.11B$5.76B$9.58BDividend YieldN/A2.23%4.41%4.10%P/E Ratio-20.1020.8831.1026.04Price / SalesN/A343.33433.45102.77Price / CashN/A43.1937.7358.48Price / Book10.038.129.536.61Net Income-$118.94M-$54.72M$3.26B$265.56M7 Day Performance2.76%2.63%2.10%1.97%1 Month Performance0.27%2.78%2.81%-0.36%1 Year Performance12.30%11.01%30.56%19.03% MoonLake Immunotherapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MLTXMoonLake Immunotherapeutics1.7764 of 5 stars$55.89+3.2%$74.43+33.2%+15.0%$3.48BN/A-20.102VTRSViatris1.6454 of 5 stars$10.63+0.2%$10.40-2.2%-9.0%$12.37B$14.74B-3.6732,000Analyst UpgradeASNDAscendis Pharma A/S3.452 of 5 stars$194.08-2.1%$242.93+25.2%+39.4%$12.13B$490.75M-37.611,017News CoverageAnalyst ForecastRDYDr. Reddy's Laboratories3.1226 of 5 stars$14.26+0.2%$16.95+18.9%-12.1%$11.87B$3.81B21.6027,811News CoverageQGENQiagen3.827 of 5 stars$48.66-1.4%$49.69+2.1%+9.4%$10.97B$1.98B28.755,765MRNAModerna4.4344 of 5 stars$28.09+0.2%$43.59+55.2%-66.5%$10.90B$3.24B-3.735,800Analyst ForecastBBIOBridgeBio Pharma4.6808 of 5 stars$49.02-4.5%$61.35+25.2%+97.2%$9.81B$221.90M-11.99400Insider TradeVRNAVerona Pharma PLC American Depositary Share2.4253 of 5 stars$105.79+0.5%$109.00+3.0%+290.2%$8.96B$42.28M-106.8630Positive NewsShort Interest ↓ELANElanco Animal Health3.0971 of 5 stars$17.72-1.4%$17.33-2.2%+22.4%$8.92B$4.44B20.609,000Analyst DowngradeBPMCBlueprint Medicines0.4892 of 5 stars$129.46flat$130.00+0.4%N/A$8.36B$562.12M-52.41640ROIVRoivant Sciences3.4485 of 5 stars$11.81-0.3%$16.50+39.7%+2.1%$8.06B$29.05M-16.87860Insider Trade Related Companies and Tools Related Companies VTRS Competitors ASND Competitors RDY Competitors QGEN Competitors MRNA Competitors BBIO Competitors VRNA Competitors ELAN Competitors BPMC Competitors ROIV Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:MLTX) was last updated on 8/23/2025 by MarketBeat.com Staff From Our PartnersBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding MoonLake Immunotherapeutics Please log in to your account or sign up in order to add this asset to your watchlist. Share MoonLake Immunotherapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access